Search research articles
Contact Us
Filters
Showing results (231-240 of 276) with videos related to
Page
of 28
Sort By:
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
International Journal of Cancer
|
July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
Sebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
Science (New York, N.Y.)
|
September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
Journal of Clinical Medicine
|
May 16, 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial
Theresa Steeb, Anja Wessely, Dagmar von Bubnoff, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Markus V Heppt, Lucie Heinzerling, Katharina C Kähler, et al.
Frontiers of Medicine
|
July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2018
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG
Uwe Hillen, Ulrike Leiter, Sylvie Haase, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 276) with videos related to
Sort By:
Page
of 28
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
International Journal of Cancer
|
July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
Sebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
Science (New York, N.Y.)
|
September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
Journal of Clinical Medicine
|
May 16, 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial
Theresa Steeb, Anja Wessely, Dagmar von Bubnoff, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Markus V Heppt, Lucie Heinzerling, Katharina C Kähler, et al.
Frontiers of Medicine
|
July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2018
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG
Uwe Hillen, Ulrike Leiter, Sylvie Haase, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Page
of 28